News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FibroGen, Inc.’s FG-3019 Granted U.S. Orphan Drug Designation for the Treatment of Patients With Idiopathic Pulmonary Fibrosis



7/31/2012 9:58:22 AM

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that FG-3019, the Company’s human monoclonal antibody against connective tissue growth factor (CTGF), has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES